Bicycle Therapeutics plc (BCYC) Financial Statements

Income statement

Metric	TTM	2025	2024	2023	2022
Revenue
Total Revenue	61.2M	72.6M	35.3M	27.0M	14.5M
Cost of Revenue	—	—	173.0M	156.5M	—
Gross Profit	61.2M	72.6M	(137.7M)	(129.5M)	14.5M
Operating Expenses
R&D Expense	200.3M	240.3M	173.0M	156.5M	81.6M
SG&A Expense	71.5M	80.0M	71.5M	59.8M	49.5M
General & Admin Expense	71.5M	80.0M	71.5M	59.8M	49.5M
Selling & Marketing Expense	—	—	—	—	—
Other Expenses	(158.0K)	—	(172.2M)	(155.9M)	—
Total Operating Expenses	271.6M	320.3M	72.2M	60.4M	131.1M
Cost and Expenses	271.6M	320.3M	245.1M	216.9M	131.1M
Operating Income (EBIT)	(210.4M)	(247.7M)	(209.9M)	(189.9M)	(116.7M)
Non-Operating
Interest Income	21.8M	28.5M	34.3M	14.0M	5.8M
Interest Expense	193.0K	206.0K	1.7M	3.3M	3.3M
Net Interest Income	21.6M	28.3M	32.6M	10.7M	2.4M
Other Non-Op Income/Expense	21.7M	28.9M	36.1M	10.7M	2.4M
Non-Operating Income (excl Interest)	(21.9M)	(29.1M)	(37.8M)	(14.0M)	(5.8M)
EBT (Pre-Tax Income)	(188.7M)	(218.8M)	(173.8M)	(179.2M)	(114.2M)
Income Tax Expense	1.7M	152.0K	(4.8M)	1.5M	(1.5M)
Bottom Line
Net Income	(190.4M)	(219.0M)	(169.0M)	(180.7M)	(112.7M)
Earnings from Cont. Ops	(190.4M)	(219.0M)	(169.0M)	(180.7M)	(112.7M)
Earnings from Discont. Ops	—	—	—	—	—
Bottom Line Net Income	(190.4M)	(219.0M)	(169.0M)	(180.7M)	(112.7M)
Per Share
Basic EPS	($2.73)	($3.16)	($2.91)	($5.08)	($3.80)
Diluted EPS	($2.73)	($3.16)	($2.90)	($5.08)	($3.80)
Revenue Per Share	$0.88	$1.05	$0.61	$0.76	$0.49
Shares
Basic Shares Outstanding	69.8M	69.3M	58.2M	35.6M	29.7M
Diluted Shares Outstanding	69.8M	69.3M	58.2M	35.6M	29.7M
Profitability Metrics
EBITDA	(183.2M)	(212.2M)	(164.9M)	(169.4M)	(107.2M)
D&A	5.3M	6.4M	7.2M	6.5M	3.7M
EBIT	(188.5M)	(218.6M)	(172.1M)	(175.9M)	(110.9M)

As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026